509 related articles for article (PubMed ID: 25336187)
1. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
2. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
3. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
6. The possible role of myostatin in skeletal muscle atrophy and cachexia.
Jespersen J; Kjaer M; Schjerling P
Scand J Med Sci Sports; 2006 Apr; 16(2):74-82. PubMed ID: 16533345
[TBL] [Abstract][Full Text] [Related]
7. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
9. Effects of the beta
Salazar-Degracia A; Busquets S; Argilés JM; Bargalló-Gispert N; López-Soriano FJ; Barreiro E
Biochimie; 2018 Jun; 149():79-91. PubMed ID: 29654866
[TBL] [Abstract][Full Text] [Related]
10. Chronic Alcohol Consumption Enhances Skeletal Muscle Wasting in Mice Bearing Cachectic Cancers: The Role of TNFα/Myostatin Axis.
Li Y; Zhang F; Modrak S; Little A; Zhang H
Alcohol Clin Exp Res; 2020 Jan; 44(1):66-77. PubMed ID: 31657476
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic analysis of the development of skeletal muscle atrophy in cancer-cachexia in tumor-bearing mice.
Blackwell TA; Cervenka I; Khatri B; Brown JL; Rosa-Caldwell ME; Lee DE; Perry RA; Brown LA; Haynie WS; Wiggs MP; Bottje WG; Washington TA; Kong BC; Ruas JL; Greene NP
Physiol Genomics; 2018 Dec; 50(12):1071-1082. PubMed ID: 30289747
[TBL] [Abstract][Full Text] [Related]
12. Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300.
Sin TK; Zhang G; Zhang Z; Zhu JZ; Zuo Y; Frost JA; Li M; Li YP
Cancer Res; 2021 Feb; 81(4):885-897. PubMed ID: 33355181
[TBL] [Abstract][Full Text] [Related]
13. Autophagic degradation contributes to muscle wasting in cancer cachexia.
Penna F; Costamagna D; Pin F; Camperi A; Fanzani A; Chiarpotto EM; Cavallini G; Bonelli G; Baccino FM; Costelli P
Am J Pathol; 2013 Apr; 182(4):1367-78. PubMed ID: 23395093
[TBL] [Abstract][Full Text] [Related]
14. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure.
Heineke J; Auger-Messier M; Xu J; Sargent M; York A; Welle S; Molkentin JD
Circulation; 2010 Jan; 121(3):419-25. PubMed ID: 20065166
[TBL] [Abstract][Full Text] [Related]
15. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
[TBL] [Abstract][Full Text] [Related]
16. Luteolin reduces cancer‑induced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model.
Chen T; Li B; Xu Y; Meng S; Wang Y; Jiang Y
Oncol Rep; 2018 Aug; 40(2):1129-1137. PubMed ID: 29845270
[TBL] [Abstract][Full Text] [Related]
17. REDD1 deletion attenuates cancer cachexia in mice.
Hain BA; Xu H; VanCleave AM; Gordon BS; Kimball SR; Waning DL
J Appl Physiol (1985); 2021 Dec; 131(6):1718-1730. PubMed ID: 34672766
[TBL] [Abstract][Full Text] [Related]
18. A non-human primate model of radiation-induced cachexia.
Cui W; Bennett AW; Zhang P; Barrow KR; Kearney SR; Hankey KG; Taylor-Howell C; Gibbs AM; Smith CP; MacVittie TJ
Sci Rep; 2016 Mar; 6():23612. PubMed ID: 27029502
[TBL] [Abstract][Full Text] [Related]
19. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.
Bonetto A; Penna F; Minero VG; Reffo P; Bonelli G; Baccino FM; Costelli P
Curr Cancer Drug Targets; 2009 Aug; 9(5):608-16. PubMed ID: 19508174
[TBL] [Abstract][Full Text] [Related]
20. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
